Denali Therapeutics Inc. Reports Q2 2026 Financial Results

What Happened

• Denali Therapeutics Inc. announced its financial results for the second quarter ended June 30, 2026. The company issued a press release on August 6, 2026, and furnished that release as Exhibit 99.1 to an 8-K under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Press release date: August 6, 2026.
• Reporting period: Quarter ended June 30, 2026.
• Exhibit: Press release furnished as Exhibit 99.1 to the Form 8-K.
• Legal note: The information and Exhibit 99.1 are furnished (not “filed”) and therefore not subject to Section 18 liability and not incorporated by reference into other SEC filings unless expressly stated.

Why It Matters

• This 8-K notifies investors that Denali has released its quarterly earnings information; the press release (Exhibit 99.1) will contain the specific financial results (e.g., revenue, net income/loss, cash position, and any guidance).
• Investors should review the attached press release for the detailed numbers and management commentary. The filing’s “furnished, not filed” status means the exhibit is provided for disclosure but is not automatically incorporated into other SEC filings.